Advaxis, Inc. (NASDAQ:ADXS) shares were down 5.4% during mid-day trading on Thursday . The stock traded as low as $0.32 and last traded at $0.35. Approximately 542,689 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 1,598,274 shares. The stock had previously closed at $0.37.
Several research analysts have recently issued reports on ADXS shares. ValuEngine upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. HC Wainwright restated a “hold” rating on shares of Advaxis in a report on Wednesday.
The firm has a market capitalization of $15.91 million, a PE ratio of -0.27 and a beta of 2.92.
A number of hedge funds have recently made changes to their positions in ADXS. Paloma Partners Management Co purchased a new stake in Advaxis in the second quarter worth $265,000. Renaissance Technologies LLC lifted its stake in Advaxis by 173.0% in the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock worth $1,120,000 after acquiring an additional 755,352 shares during the period. Vanguard Group Inc lifted its stake in Advaxis by 48.3% in the third quarter. Vanguard Group Inc now owns 2,630,658 shares of the biotechnology company’s stock worth $2,473,000 after acquiring an additional 857,026 shares during the period. Finally, Virtu Financial LLC lifted its stake in Advaxis by 740.4% in the fourth quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 155,246 shares during the period. 29.79% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2019/01/17/advaxis-adxs-shares-down-5-4.html.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
See Also: What is the float in trading stocks?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.